Merck
-
Daiichi Sankyo, Merck withdraw FDA BLA for lung cancer drug in US
The withdrawal changes the immediate US regulatory path for the ES-SCLC indication, but the ongoing Phase III programme provides the companies with another source of clinical data.
-
Merck signs early voluntary licenses for investigational monthly HIV prevention pill
The agreements are nonexclusive and cover Aspen Pharmacare, Quality Chemical Industries and UCL Kenya in sub-Saharan Africa, as well as Aurobindo, Cipla, Emcure and Viatris in India.
-
Gilead, Merck present pivotal Phase 3 Islend data for first once-weekly oral HIV regimen
Researchers presented the findings at the 26th International AIDS Conference in Rio de Janeiro, Brazil.
-
Merck secures landmark FDA approval for cholesterol pill Lipfendra
The approval marks the first oral PCSK9 inhibitor, offering patients an alternative to injectable therapies traditionally used to reduce LDL cholesterol levels.
-
Merck KGaA to acquire Bio-Techne for US$11.3B in major life sciences expansion
The acquisition is expected to strengthen Merck’s position in the rapidly growing life sciences sector, particularly in areas such as cell and gene therapy, precision diagnostics, multi-omics research, and biopharmaceutical manufacturing.
-
Protillion Biosciences secures US$510M Merck deal for AI biologics discovery
The agreement brings together Protillion’s computational biology platform with Merck’s established drug development expertise to support the discovery of next-generation therapies.
-
Merck expands HIV portfolio with FDA approval of Idvynso single-tablet regimen
The tablet combines 100 mg of doravirine and 0.25 mg of islatravir in a once-daily formulation.
-
Merck completes US$6.7B acquisition of Terns Pharmaceuticals to strengthen the leukemia drug pipeline
Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.
-
European Commission approves Merck’s Enflonsia for RSV prevention in infants
The approval grants the pharmaceutical giant the right to market Enflonsia across all 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway.
-
Merck restructures China vaccine deal as Gardasil demand collapses
This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.